1202 related articles for article (PubMed ID: 19406595)
21. Screening for cancer with PET and PET/CT: potential and limitations.
Schöder H; Gönen M
J Nucl Med; 2007 Jan; 48 Suppl 1():4S-18S. PubMed ID: 17204716
[TBL] [Abstract][Full Text] [Related]
22. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
23. Fever of unknown origin: the role of 18F-FDG PET/CT.
Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
[TBL] [Abstract][Full Text] [Related]
24. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
Brechtel K; Klein M; Vogel M; Mueller M; Aschoff P; Beyer T; Eschmann SM; Bares R; Claussen CD; Pfannenberg AC
J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
[TBL] [Abstract][Full Text] [Related]
25. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
26. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.
Rodrigues RS; Bozza FA; Christian PE; Hoffman JM; Butterfield RI; Christensen CR; Heilbrun M; Wiggins RH; Hunt JP; Bentz BG; Hitchcock YJ; Morton KA
J Nucl Med; 2009 Aug; 50(8):1205-13. PubMed ID: 19617339
[TBL] [Abstract][Full Text] [Related]
27. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions.
Shammas A; Lim R; Charron M
Radiographics; 2009; 29(5):1467-86. PubMed ID: 19755606
[TBL] [Abstract][Full Text] [Related]
28. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
Karantanis D; O'Neill BP; Subramaniam RM; Peller PJ; Witte RJ; Mullan BP; Wiseman GA
Clin Nucl Med; 2007 Apr; 32(4):271-4. PubMed ID: 17413571
[TBL] [Abstract][Full Text] [Related]
29. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
30. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers.
Breen SL; Publicover J; De Silva S; Pond G; Brock K; O'Sullivan B; Cummings B; Dawson L; Keller A; Kim J; Ringash J; Yu E; Hendler A; Waldron J
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):763-70. PubMed ID: 17379435
[TBL] [Abstract][Full Text] [Related]
31. F-18 FDG PET/CT staging of multiple myeloma with diffuse osseous and extramedullary lesions.
Wiesenthal AA; Nguyen BD
Clin Nucl Med; 2007 Oct; 32(10):797-801. PubMed ID: 17885362
[TBL] [Abstract][Full Text] [Related]
32. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.
Pfannenberg C; Aschoff P; Schanz S; Eschmann SM; Plathow C; Eigentler TK; Garbe C; Brechtel K; Vonthein R; Bares R; Claussen CD; Schlemmer HP
Eur J Cancer; 2007 Feb; 43(3):557-64. PubMed ID: 17224266
[TBL] [Abstract][Full Text] [Related]
33. FDG-PET in the clinical management of Hodgkin lymphoma.
Hutchings M; Eigtved AI; Specht L
Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
[TBL] [Abstract][Full Text] [Related]
34. Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging.
Kinner S; Antoch G; Bockisch A; Veit-Haibach P
Abdom Imaging; 2007; 32(5):606-12. PubMed ID: 17387540
[TBL] [Abstract][Full Text] [Related]
35. The role of PET in lymphoma.
Jhanwar YS; Straus DJ
J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
38. Giant cell arteritis on 18F-FDG PET/CT.
Heston TF; Szabo Z
Clin Physiol Funct Imaging; 2009 Sep; 29(5):382-4. PubMed ID: 19522856
[TBL] [Abstract][Full Text] [Related]
39. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
Avril N; Dambha F; Murray I; Shamash J; Powles T; Sahdev A
Int J Urol; 2010 Jun; 17(6):501-11. PubMed ID: 20370848
[TBL] [Abstract][Full Text] [Related]
40. Considerations for generic oncology FDG-PET/CT protocol preparation in drug development.
Hallett WA; Maguire RP; McCarthy TJ; Schmidt ME; Young H
IDrugs; 2007 Nov; 10(11):791-6. PubMed ID: 17968761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
